Glucagon-like Peptide-1 (GLP-1) Agonists Market Size (2024 - 2029)

The Glucagon-like Peptide-1 Agonists Market is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes and the drug class's benefits in managing hyperglycemia and other related conditions. The market's expansion is further supported by the medications' additional anti-inflammatory and pulmonary protective effects, which have made them relevant in treating COVID-19 complications. Technological advancements in drug formulations and the rising global diabetes population are also contributing factors to the anticipated growth in market size.

Market Size of Glucagon-like Peptide-1 (GLP-1) Agonists Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary
Study Period 2019- 2029
Market Size (2024) USD 11.99 Billion
Market Size (2029) USD 12.63 Billion
CAGR (2024 - 2029) 1.12 %
Fastest Growing Market Middle East and Africa
Largest Market North America

Major Players

Glucagon-like Peptide-1 (GLP-1) Agonists Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis

The Glucagon-like Peptide-1 Agonists Market size is estimated at USD 11.99 billion in 2024, and is expected to reach USD 12.63 billion by 2029, growing at a CAGR of 1.12% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the GLP-1RA drug or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Glucagon-like Peptide-1 (GLP-1) Agonists Industry Segmentation

GLP-1 receptor agonists are a non-insulin medication combined with diet and exercise to help treat type 2 diabetes. The Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide(Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), and Semaglutide (Ozempic)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Drugs
Dulaglutide
Trulicity
Exenatide
Byetta
Bydureon
Liraglutide
Victoza
Lixisenatide
Lyxumia
Semaglutide
Ozempic
Geography
North America
United States
Canada
Rest of North America
Europe
Germany
Spain
Italy
France
United Kingdom
Russia
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Malaysia
Indonesia
Thailand
Philippines
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
South Africa
Saudi Arabia
Oman
Egypt
Iran
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

Glucagon-like Peptide-1 (GLP-1) Agonists Market Size Summary

The Glucagon-like Peptide-1 (GLP-1) Agonists Market is poised for growth, driven by the increasing prevalence of type 2 diabetes and obesity, alongside supportive government initiatives. These medications, which include drugs like Dulaglutide, are pivotal in managing diabetes due to their lower risk of hypoglycemia compared to older treatments and their additional benefits such as weight loss and cardiovascular protection. The market has seen a positive impact from the COVID-19 pandemic, as GLP-1RAs have been recognized for their potential benefits in managing diabetes-related complications and improving immune response. The market landscape is characterized by the presence of major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, which are actively involved in the development and distribution of these therapies globally.

North America currently holds a significant share of the GLP-1 Agonists Market, with a substantial number of adults living with diabetes or prediabetes, particularly among underserved communities. The approval of new formulations, such as the oral GLP-1 agonist Rybelsus, and the introduction of weight loss injections like Wegovy, highlight the ongoing innovation and expansion within the market. These advancements, coupled with the rising demand for effective diabetes management solutions, are expected to sustain the market's growth trajectory over the forecast period. The market's consolidation with key players ensures a competitive environment, fostering further developments and accessibility of GLP-1 therapies across various regions.

Explore More

Glucagon-like Peptide-1 (GLP-1) Agonists Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drugs

      1. 2.1.1 Dulaglutide

        1. 2.1.1.1 Trulicity

      2. 2.1.2 Exenatide

        1. 2.1.2.1 Byetta

        2. 2.1.2.2 Bydureon

      3. 2.1.3 Liraglutide

        1. 2.1.3.1 Victoza

      4. 2.1.4 Lixisenatide

        1. 2.1.4.1 Lyxumia

      5. 2.1.5 Semaglutide

        1. 2.1.5.1 Ozempic

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Rest of North America

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 Spain

        3. 2.2.2.3 Italy

        4. 2.2.2.4 France

        5. 2.2.2.5 United Kingdom

        6. 2.2.2.6 Russia

        7. 2.2.2.7 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 Japan

        2. 2.2.3.2 China

        3. 2.2.3.3 Australia

        4. 2.2.3.4 India

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Malaysia

        7. 2.2.3.7 Indonesia

        8. 2.2.3.8 Thailand

        9. 2.2.3.9 Philippines

        10. 2.2.3.10 Rest of Asia-Pacific

      4. 2.2.4 Latin America

        1. 2.2.4.1 Brazil

        2. 2.2.4.2 Mexico

        3. 2.2.4.3 Rest of Latin America

      5. 2.2.5 Middle East and Africa

        1. 2.2.5.1 South Africa

        2. 2.2.5.2 Saudi Arabia

        3. 2.2.5.3 Oman

        4. 2.2.5.4 Egypt

        5. 2.2.5.5 Iran

        6. 2.2.5.6 Rest of Middle East and Africa

Glucagon-like Peptide-1 (GLP-1) Agonists Market Size FAQs

The Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion in 2024 and grow at a CAGR of 1.12% to reach USD 12.63 billion by 2029.

In 2024, the Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion.

GLP-1 Agonist Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)